Ablation Technology Market to Hit USD 15.4 Billion by 2031 as Pulsed Field and AI Guided Procedures Accelerate
Chicago, 2nd june 2025 — Clearview Market Insights (CVMI) forecasts that the global ablation technology market will grow from USD 7.5 billion in 2024 to USD 15.4 billion by 2031, reflecting a robust compound annual growth rate (CAGR) of 10.8 percent. Demand is driven by surging atrial fibrillation (AF) caseloads, rapid adoption of minimally invasive oncology treatments, and breakthrough energy modalities such as pulsed field ablation (PFA) and high intensity focused ultrasound (HIFU).
“Energy‑based ablation is reshaping how clinicians treat arrhythmias,
tumors, chronic pain, and more,” said Dr Alexandra Hart, Interventional Devices
Lead Analyst at CVMI. “With AI‑guided mapping, robotics, and non‑thermal tissue‑selective
pulsed fields, safety profiles are improving while procedure times drop—opening
the door to broader outpatient adoption.”
Request Sample @ https://clearviewmarketinsights.com/report-details/global-ablation-technology-market/
Key Figures
Metric |
2024 |
2031 |
CAGR (2024‑31) |
Market Size (USD B) |
7.5 |
15.4 |
10.8 % |
Cardiac Electrophysiology
Share |
46 % |
48 % |
— |
Oncology Ablation Share |
32 % |
31 % |
— |
Asia‑Pacific CAGR |
— |
13.1 % |
— |
Growth Catalysts
- Aging
& AF Epidemic — Estimated 12 million AF patients in
the U.S. by 2030; catheter ablation adoption rises.
- Next‑Gen
Energy — PFA catheters show single‑shot
pulmonary‑vein isolation in <15 minutes with low esophageal risk.
- Oncology
Shift — Liver, kidney, lung, and bone tumors
increasingly treated percutaneously with microwave and cryo technologies.
- Robotics
& AI — Contact‑force sensors and AI mapping
reduce fluoroscopy time and improve lesion durability.
- Outpatient
Migration — Ambulatory surgery centers capture
rising share of pain and thyroid ablation procedures.
Leading Players
Company |
2024 Share |
Recent Highlight |
Medtronic |
22 % |
CE Mark for PulseSelect™ PFA; global
launch in progress |
Boston Scientific |
18 % |
Completed FARAPULSE IDE; U.S. approval expected
2025 |
Johnson & Johnson –
Biosense Webster |
16 % |
Opti‑PFA catheter pilot in EU;
CARTO™ AI mapping upgrade |
Abbott |
11 % |
FDA clearance for FlexAbility™ SE with contact‑force
feedback |
AngioDynamics |
6 % |
NanoKnife™ electroporation
prostate IDE underway |
Regional Snapshot
- North
America — Largest revenue share (43 %); CMS adds
outpatient AF ablation codes.
- Europe — Early PFA adoption in Germany, UK; robust HIFU therapy for
uterine fibroids.
- Asia‑Pacific — Fastest growth; China expands microwave liver‑tumor programs,
Japan subsidies cardiac PFA.
- Latin
America — RF and cryo dominate; Brazil funds
public‑sector pain‑ablation centers.
- Middle
East & Africa — Gulf cardiac institutes pilot robotic
RF labs; oncology HIFU adoption begins.
2024‑25 Milestones
Quarter |
Event |
Effect |
Q4 2023 |
Medtronic PulseSelect™ PFA CE
Mark |
First non‑thermal AF system
approved in EU |
Q2 2024 |
Boston Scientific completes FARAPULSE IDE |
Sets stage for 2025 FDA submission |
Q3 2024 |
AngioDynamics starts
NanoKnife™ prostate IDE |
Opens new urologic application
vertical |
Q4 2024 |
Chinese CFDA fast‑tracks domestic HIFU console |
Boosts local oncology capacity |
Q1 2025 |
Abbott FlexAbility™ SE U.S. clearance |
Expands contact‑force RF
portfolio |
Technology Trends
- Pulsed‑Field
Ablation — Non‑thermal electroporation
selectively targets myocardium, reducing collateral damage risk.
- Robotic
Navigation — Robotic arms stabilize catheters,
cutting radiation exposure by up to 40 %.
- AI
Lesion Assessment — Real‑time algorithms quantify lesion
depth and predict reconnection gaps.
- Hybrid
Ablation Suites — Combined RF‑microwave systems treat
multifocal liver tumors.
- Eco‑Smart
Disposables — Recyclable catheter housings and gas‑free
cryo alternatives reduce environmental impact.
Looking Forward
- 2025 — U.S. approval of first PFA system triggers wave of outpatient AF
centers.
- 2026 — HIFU receives FDA clearance for pancreatic tumor palliation.
- 2027 — AI‑guided lesion durability metrics standard in EU
electrophysiology labs.
- 2028 — Single‑use robotic arms enter oncology ablation, slashing
capital barriers.
- 2029 — Global electroporation oncology revenues surpass USD 1 billion.
- 2030 — Pulsed‑field systems account for 40 % of new AF ablation
installs.
- 2031 — Over 70 % of liver and kidney ablations performed in ambulatory
settings.
For more
insights, visit https://clearviewmarketinsights.com/
About Clearview Market Insights:
Clearview Market Insights is a leading market research and
consulting firm providing in-depth industry analysis and strategic
recommendations for businesses worldwide.
Media contact:
Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369
Comments
Post a Comment